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Abstract
Bridging the gap between animal or in vitro models and human disease is essential in medical research. Researchers often
suggestthatabiologicalmechanismisrelevanttohumancancerfromthestatisticalassociationofageneexpression marker (a
signature) of this mechanism, that was discovered in an experimental system, with disease outcome in humans. We examined
this argument for breastcancer. Surprisingly, we found that geneexpression signatures—unrelatedto cancer—of the effect of
postprandial laughter, of mice social defeat and of skin fibroblast localization were all significantly associated with breast
cancer outcome. We next compared 47 published breast cancer outcome signatures to signatures made of random genes.
Twenty-eight of them (60%) were not significantly better outcome predictors than random signatures of identical size and 11
(23%) were worst predictors than the median random signature. More than 90% of random signatures .100 genes were
significant outcome predictors. We next derived a metagene, called meta-PCNA, by selecting the 1% genes most positively
correlated with proliferation marker PCNA in a compendium of normal tissues expression. Adjusting breast cancer expression
data for meta-PCNA abrogated almost entirely the outcome association of published and random signatures. We also found
that, in the absence of adjustment, the hazard ratio of outcome association of a signature strongly correlated with meta-PCNA
(R
2=0.9). This relation also applied to single-gene expression markers. Moreover, .50% of the breast cancer transcriptome
was correlated with meta-PCNA. A corollary was that purging cell cycle genes out of a signature failed to rule out the
confounding effect of proliferation. Hence, it is questionable to suggest that a mechanism is relevant to human breast cancer
from the finding that a gene expression marker for this mechanism predicts human breast cancer outcome, because most
markers do. The methods we present help to overcome this problem.
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Introduction
Ethics limits experimental investigation on human subjects.
Hence, most experimental biomedical research is performed on
animal and/or in vitro models. Proving that findings from model
systems are relevant to human health is a major bottleneck.
Hundreds of studies in oncology have suggested the biological
relevance to human of putative cancer-driving mechanisms with
the following three steps: 1) characterize the mechanism in a
model system, 2) derive from the model system a marker whose
expression changes when the mechanism is altered, and 3) show
that marker expression correlates with disease outcome in
patients—the last figure of such paper is typically a Kaplan-Meier
plot illustrating this correlation.
Breast cancer has been a test bed in oncogenomics. Several
landmark studies (reviewed in ref. [1]) uncovered multi-gene
mRNA markers of disease recurrence, which are independent of
classical clinical markers and may provide useful information to
guide treatment. These clinically motivated multi-genes markers,
also called signatures, were derived from compendia of genome-
wide mRNA tumoral profiles by selecting genes whose expression
correlated with outcome [2–5], or with known aggressiveness
markers such as proliferation [6–9] or grade [10–12].
Beyond clinical utility, many signatures were derived as markers
of specific mechanisms and/or biological states and their
association with outcome was evaluated in the context of studies
structured along the 3-steps outlined above. These include
signatures of stem cells [13–15], aneuploidy [16], wound healing
[17,18], hypoxia [19,20], stromal component [21], epithelial-
mesenchymal transition [22–24]; of mutations in TP53 [25],
ALK5 [26]; of loss of PTEN [27]; of perturbations of E2F1 [28],
bromodomain 4 [29], mir31 targets [30], p18
ink4c [31], retinoic
acid receptor [32]; of anchorage-independent growth [33],
activation of modules related to the proteasome and mitochon-
drions [34], etc. Contrasting with this diversity, meta-analyses of
several outcome signatures have shown that they have essentially
equivalent prognostic performances [35,36], and are highly
correlated with proliferation [7–8,37], a predictor of breast cancer
outcome that has been used for decades [38–40].
This raises a question: are all these mechanisms major
independent drivers of breast cancer progression, or is step #3
inconclusive because of a basic confounding variable problem? To
take an example of complex system outside oncology, let us
suppose we are trying to discover which socio-economical
variables drive people’s health. We may find that the number of
TV sets per household is positively correlated with longer life
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health. Life expectancy and TV sets per household are both
correlated with the gross national product per capita of nations, as
are many other causes or byproducts of wealth such as energy
consumption or education. So, is the significant association of say, a
stem cell signature, with human breast cancer outcome informative
about the relevance of stem cells to human breast cancer?
Resolving this issue has become more pressing recently. Several
large cohorts with genome-wide tumoral expression profiles and
patient follow-ups are available in the public domain. Servers
resting on these data [41,42] make step #3 accessible to anyone
with an Internet connection. Genome-wide expression profiling
has also considerably lowered the barrier to step #2. The search
for markers is reduced to a nearly automated screen by comparing
microarray profiles in situations where the putative cancer-driving
mechanism is active or inactive. The end result is an increasing
number of signatures.
Few studies using the outcome-association argument present
negative controls to check whether their signature of interest is
indeed more strongly related to outcome than signatures with no
underlying oncological rationale. In statistical terms, these studies
typically rest on H0 assuming a background of no association with
outcome. The negative controls we present here prove this
assumption wrong: a random signature is more likely to be
correlated with breast cancer outcome than not. The statistical
explanation for this phenomenon lies in the correlation of a large
fraction of the breast transcriptome with one variable, we call it
meta-PCNA, which integrates most of the prognostic information
available in current breast cancer gene expression data.
Results
Most signatures not biologically related to cancer are
statistically associated with breast cancer outcome
In order to assess whether association with outcome was
specific, we tested the association with breast cancer outcome of
three signatures whose rationale does not suggest any connection
with cancer: a signature of the effect of postprandial laughter on
peripheral blood mononuclear cells [43], a signature of skin
fibroblast localization [44] and a signature of social defeat
obtained from mice brains [45]. For the sake of simplicity, and
because this is the most commonly used setup in the field, we
focused on the 295 patients of the Netherlands Cancer Institute
(a.k.a. NKI) cohort [2] and the overall survival end-point. Details
on the procedure used to estimate association with outcome are
provided in Supporting Information (Text S1). Surprisingly, the
three control signatures were significantly associated with outcome
(Figure 1, panels A–C).
To check that these were not anecdotal observations, we
downloaded all signatures from MSigDB database [46] belonging
to the c2 category and assessed their association with outcome.
MSigDB c2 signatures are manually curated from the literature on
gene expression and also include gene sets from curated pathways
databases such as KEGG. Trivial single-gene signatures were
removed. The 1890 signatures examined in MSigDB c2
encompass all the fields of biomedical sciences, nevertheless we
discovered that 67% of them were associated with breast cancer
outcome at p,0.05, 23% at p,10
25 (Figure 1D).
Cancer is a major subject matter of biomedical research, thus
MSigDB c2 may be enriched for cancer-related signatures. To rule
out the potential effect of a cancer bias, we generated for each
signature in MSigDB c2 a signature of identical size but selected its
genes randomly in the human genome. Although they are
completely devoid of any biological rationale, 77% of these
signatures were associated with outcome at p,0.05, and 30% at
p,10
25 (Figure 1D).
Thus, nominal p-values should not be used directly because a
signature associated with outcome with a significance of 10
25 and
even more so, 0.05, is not more related to outcome than a random
set of genes.
Most published breast cancer signatures are not more
strongly associated with breast cancer outcome than sets
of random genes
Although most random signatures are significantly associated
with breast cancer outcome, the association could be much
stronger for published breast cancer signatures and provide valid
statistical support for their relevance.
We compiled 47 signatures from the literature. Association with
outcome has been reported for most of them (Supporting
Information, Text S1), either for the purpose of finding better
prognostic tools, or, in most cases, to suggest biological relevance.
We compared the outcome association of each signature to that of
1000 random signatures of identical size (Figure 2). We confirmed
the outcome association of 42 in these 47 signatures. Yet, 11 of
them (23%) showed a weaker association than the median of
random signatures. Abiding to statistical standard, one may
consider a signature biologically relevant if its association with
outcome is stronger than the association of the best 5% random
signatures. Only 18 signatures in 47 (40%) met this criterion.
Figure 2 reveals that larger signatures are more significant.
More than 90% of the signatures .100 genes we generated were
significant at p,0.05. For the two largest ones, 714 and 1345
genes respectively, all 1000 random signatures tested were
significant.
At the other end of the size spectrum, we found that 26% of
individual genes printed on the NKI arrays were associated with
outcome at p,0.05. Thus, a single gene study has 26 chances in
100 to yield a significant association. When we applied a q-value
correction [47]—relevant to genome-wide studies—17% of all
genes were associated with outcome at q,0.05. A comparable
calculation was presented by Ein-Dor et al. [48]: 1234 genes
Author Summary
Proving that research findings from in vitro or animal
models are relevant to human diseases is a major
bottleneck in medical science. Hundreds of researchers
have suggested the human relevance of oncogenic
mechanisms from the statistical association between gene
expression markers of these mechanisms and disease
outcome. Such evidence has become easier to obtain
recently with the advent of microarray screens and of large
public-domain genome-wide expression datasets with
patient follow-up. We demonstrated that in breast cancer
any set of 100 genes or more selected at random has a
90% chance to be significantly associated with outcome.
Thus, investigators are bound to find an association
however whimsical their marker is. For example, we could
establish outcome associations for a signature of post-
prandial laughter and a signature of social defeat in mice.
Association was not stronger than expected at random for
28 (60%) of 47 published breast cancer signatures. The
odds of association are 5–17% with random single gene
markers—a finding relevant to older breast cancer studies.
We explained these results by showing that much of the
breast cancer transcriptome is correlated with prolifera-
tion, which integrates most prognostic information in this
disease.
Random Signatures Are Prognostic in Breast Cancer
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outcome with a false discovery rate ,10%.
Meta-PCNA integrates most of the outcome-related
signal contained in the breast cancer transcriptome
Proliferation is a well-known breast cancer prognostic marker
[38–40]. Cycling cells express thousands of specific genes [49],
thus genome-wide expression profiles are likely to capture the
fraction of cycling cells within a tissue. A proliferation cluster was
noticed in early breast cancer microarray studies [50–52], and
proliferation is the major variable behind gene expression-based
breast cancer prognosis [7–9]. We devised a new metagene, meta-
PCNA, in order to investigate further the role of proliferation.
The proliferating cell nuclear antigen, PCNA, is a ring-shaped
protein that encircles DNA and regulates several processes leading
to DNA replication [53]. As suggested by its name, this is one of
the most widely used antigen target for immunohistochemical
measures of the fraction of proliferating cells in tissues. Ge et al.
[54] profiled with microarrays 36 tissues from normal, healthy,
individuals encompassing 27 organs. We call ‘meta-PCNA’ the
signature composed of the 1% genes the most positively correlated
with PCNA expression across these 36 tissues (Table S1). In plain
language, meta-PCNA genes are consistently expressed when
PCNA is expressed in normal tissues and consistently repressed
when PCNA is repressed. We define the meta-PCNA index as the
median expression of meta-PCNA genes. Beside PCNA itself,
meta-PCNA includes other canonical proliferation markers such
as MKI67, TOP2A, MCM2, etc.
We next compared for each one of the 47 published signatures its
association with outcome in the original NKI data set and after
adjustment of expression levels for the meta-PCNA index (Figure 3,
Kaplan-Meier plots in Supporting Information, Text S1). Their
association with outcome dropped dramatically after adjustment,
although a few signatures remained strongly outcome associated.
Any transformation damaging expression data will trivially decrease
the association between outcome and expression. To control that
was not the case with our adjustment procedure we reran the same
analysis, except that meta-PCNA values were permuted randomly
among patients prior to adjustment. In contrast with the adjustment
of the actual non-permuted index, outcome association was not
affected (Supporting Information, Text S1).
We plotted the hazard ratios of the 47 signatures against the
absolute correlation of their first principal component with the
meta-PCNA index. The more a signature was correlated with
meta-PCNA, the higher its hazard ratio (R
2=0.9, Figure 4A,
details for each data point in Supporting Information, Text S1).
Since only a limited set of genes is included in the 47 signatures,
we plotted the distribution of correlations with the meta-PCNA
index of all genes significantly associated with outcome and, as a
negative control, of all genes printed on the microarrays
(Figure 4B). Among the 17% of genes associated with outcome
at q,0.05, 91% were significantly correlated with meta-PCNA.
Thus, any predictor resting on a linear combination of genes
associated with outcome has a high probability to be confounded
by proliferation.
More than 50% of the breast cancer transcriptome is
correlated with meta-PCNA, hence removing cell cycle
genes from a signature cannot rule out proliferation as a
confounder
The potential confounding effect of proliferation has been
recognized by a number of authors who attempted to rule it out by
removing known proliferation genes from expression data
[17,14,15]. These genes have been defined in various ways,
including the Gene Ontology ‘cell cycle’ category, the genes
periodically regulated in a cell-cycle time course [49], or genes of
the breast cancer ‘proliferation cluster’ [55].
Following Ben Porath et al. [14], we defined as cell-cycle genes
any gene present in at least one of these three categories. We
calculated the distributions of correlations between the meta-
PCNA index and genes of the Embryonic Stem Cell Module
(ESCM) of Wong et al. [15], with and without the cell cycle genes
(Figure 5). Purging these genes out of the ESCM did eliminate
signals in the highest correlation range, but the ESCM remained
vastly more correlated with meta-PCNA than the bulk of genes
printed on the arrays (p=10
225).
Moreover, 58% of the genes printed on the array were
significantly correlated with the meta-PCNA index in the NKI
cohort. Thus, the correlations with meta-PCNA extend far beyond
cell cycle genes. Removing these genes fails to rule out the
confounding effect of proliferation. Similarly, a signature does not
have to be enriched with known cell cycle genes to convey a strong
cell proliferation signal.
Results are reproducible across cohorts and end-points
Previous sections rested on the NKI data set and the overall
survival end-point. Are our observations specific of this popular,
but not universal, setup? We reran the analyses using recurrence-
free survival, and on another cohort [56] using both overall
survival and relapse-free survival.
We calculated hazard ratios for the 47 published signatures
using all combinations of end-points and cohorts. Correlation
between hazard ratios among the different cohorts/end-points was
$0.97 (Figure 6). Thus, the ranking of the signatures with respect
to association with outcome was highly reproducible. However,
Figure 1. Association of negative control signatures with overall survival. In plots A–C the NKI cohort was split into two groups using a
signature of post-prandial laughter (panel A), localization of skin fibroblasts (panel B), social defeat in mice (panel C). In panels A–C, the fraction of
patients alive (overall survival, OS) is shown as a function of time for both groups. Hazard ratios (HR) between groups and their associated p-values
are given in bottom-left corners. Panel D depicts p-values for association with outcome for all MSigDB c2 signatures and random signatures of
identical size as MSigDB c2 signatures.
doi:10.1371/journal.pcbi.1002240.g001
Random Signatures Are Prognostic in Breast Cancer
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ratios ,1.3 units higher (median HR=3.8 in NKI and OS vs.
,2.5 in other setups). Accordingly, p-values were ,4 orders of
magnitude smaller than when association with outcome was
estimated from the overall survival in the cohort of Loi et al. [56],
although it included ,30% more patients. This difference
between the 2 cohorts is less marked with relapse-free survival.
Nevertheless, our analysis (summarized Table 1) reveals that,
irrespective of the specific setup, at least 40% of MSigDB c2
signatures and 5% of all genes are associated with outcome, and at
most 40% of the 47 published signatures are better than the 5%
best same-size random signatures.
Discussion
There are many ways to estimate association between the
expression of a multi-gene marker and disease outcome, and
different studies have taken different routes. Our goal to compare
signatures and assess them against negative controls, however,
implied a uniform statistical framework. We present a comparison
of a number of such methods in the Supporting Information (Text
S1). A popular approach used in the studies we reviewed consists
in stratifying the patients by hierarchical clustering in the signature
subspace [57,21,29,24,28,15,58]. In most cases, our method of
choice (using the first component of a Principal Components
Analysis of a signature as a prognostic score) reveals stronger
outcome associations than this approach. Our method is validated
by the fact that we could reproduce the outcome association of
most published signatures, which, conversely, validates the
prognostic value of those signatures. The choice of association
method is of course important, as there is a possibility that it misses
some signals captured by specific combinations of signatures and
models. However, most papers use similarly simple methods as
ours. Furthermore, the strength of such association might be
doubted if it depended on an elaborate algorithm, as it is likely to
be caused by spurious signals arising from model selection biases.
The main message of this paper is that, if the purpose of a study
is to assert the biological relevance to human cancer of a signature,
the association between this signature and outcome cannot rest on
the nominal p-values, as obtained on breast cancer by the Cox
analysis. This follows from elevated likelihood that random sets of
genes are related to the outcome. Thus, an investigator finding
that her/his signature is associated with outcome with a
significance of 10
25, and even more so, 0.05, gains no specific
information because sets of random genes would likely yield
similar, or better, results. Nominal p-values do not answer the
appropriate statistical question: the question is not whether a given
set of genes is related to survival, but whether it is more related to
survival than random sets of genes.
This problem extends to single-gene markers and therefore to
many studies published in the pre-genomic era. Claims similar to
those concerning signatures have been made, that single genes,
important in a model system, are relevant for human cancer
progression based on differential expression between short- and
long-survival groups. As 26% of the genes are related to survival at
p,0.05 (17% at q,0.05), much tighter p-values than commonly
used should be imposed to demonstrate such a relation.
Several studies in the panel of 47 we investigated developed
arguments independent of outcome association. For example, Hu
et al. [59] used outcome association not as a validation argument,
but as an exploratory tool to discover driver DNA copy number
aberrations, which were then directly investigated. However, most
of these studies, and many more not reviewed here, extrapolatedthe
results fromanimal orhighlyartificialin vitro models to human in vivo
cancer on the basis of questionable association statistics alone.
The present study addresses purely correlative association
between gene-expression and disease outcome. We have shown
that proliferation integrates most of the prognostic information
contained in the breast cancer transcriptome. Yet—we cannot
stress this enough—we have not shown that proliferation is a core
driving force behind breast cancer progression. Disentangling the
role of a biological process in cancer progression in vivo from the
role of proliferation and from the role of the other processes
associated with it is a crucial issue. The adjustment methodology
we propose may be useful in assessing whether markers of
biological processes do or do not rest on association with
proliferation. Our results also imply that such markers should be
Figure 2. Most published signatures are not significantly better
outcome predictors than random signatures of identical size.
The x-axis denotes the p-value of association with overall survival. Red
dots stand for published signatures, yellow shapes depict the
distribution of p-values for 1000 random signatures of identical size,
with the lower 5% quantiles shaded in green and the median shown as
black line. Signatures are ordered by increasing sizes.
doi:10.1371/journal.pcbi.1002240.g002
Random Signatures Are Prognostic in Breast Cancer
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control markers.
Our study questions the biological interpretation of the
prognostic value of published breast cancer signatures, but has
no bearing on their usefulness in the clinic: a marker may be
accurate without yielding interesting biological insight regarding
the mechanism of disease progression. Nevertheless, the promi-
nence of proliferation should be taken into account in future
clinical research. Are there transcriptional signals in breast cancer
that are prognostic, but independent of proliferation? Is there any
hope to perform better than the 70 genes NKI signature [2]? The
studies we reviewed assessed outcome prediction from gene
expression measured in bulk tumors sampled from a relatively
wide spectrum of patients, thus prognostic transcriptional signals
detectable in specific tumor cells and/or specific patient groups
were out of scope. Yet, proliferation-related signals are prognostic
mostly in ER+ tumors [1]. Immunological genes convey
prognostic information in ER- tumors and in tumors with
HER2 amplification [8,60–64]. This information is unquestion-
ably independent of proliferation since it improves prognostic
accuracy beyond the abilities of proliferation-driven signatures and
classical clinical markers [65]. Larger cohorts allowing the analysis
of patients sub-groups and expression profiling of specific tumor
cells/tumor areas may lead to better prognostic tools in the future.
In conclusion, we have shown that 1) random single- and
multiple-genes expression markers have a high probability to be
associated with breast cancer outcome; 2) most published
signatures are not significantly more associated with outcome
than random predictors; 3) the meta-PCNA metagene integrates
most of the outcome-related information contained in the breast
cancer transcriptome; 4) this information is present in over 50% of
the transcriptome and cannot be removed by purging known cell-
cycle genes from a signature.
Methods
Software setup
All analyses were run with R 2.9.0 [66] with packages specified
in the following sections. Functions were run with default
parameters unless specified otherwise.
Figure 3. Meta-PCNA adjustment decreases the prognostic
abilities of published signatures. Hazard ratios for overall survival
association of 48 signatures in the original dataset (blue) and the meta-
PCNA-adjusted dataset (red). Box sizes are inversely related to the size
of the confidence intervals. Related Kaplan-Meier plots are available in
the Supporting Information (Text S1).
doi:10.1371/journal.pcbi.1002240.g003
Figure 4. Most prognostic transcriptional signals are correlated
with meta-PCNA. A) Each point denotes a signature. The x-axis
depicts the absolute value of the correlation of the first principal
component of the signatures with meta-PCNA, the y-axis depicts the
hazard ratio for outcome association. Details of the analysis for each
data point are available in the Supporting Information (Text S1). B)
Distribution of the correlations of individual genes with meta-PCNA, for
genes significantly associated with overall survival (red) and for all the
genes spotted on the microarrays (black).
doi:10.1371/journal.pcbi.1002240.g004
Random Signatures Are Prognostic in Breast Cancer
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The code and data underlying the results and figures of this
study are available as a Bzip2-compressed tar bundle from the
PLoS Computational Biology web site (Dataset S1, size is 87 MB). The
scripts assume a UNIX/LINUX environment.
Expression data
All the data were available from public sources:
N Ge et al. [54] data were downloaded from NCBI’s Gene
expression Omnibus (www.ncbi.nlm.nih.gov/geo; accession,
GDS1096). We renormalized the raw data (CEL files) using
Bioconductor [67] package gcrma [68].
N Loi et al. [56] data were downloaded from NCBI’s Gene
expression Omnibus (accession GSE6532). We used the Rdata
file.
N The NKI, a.k.a. van de Vijver et al. [2], data set was
downloaded from the Rosetta Inpharmatics web site on April
26
th 2007 (www.rii.com, this site is now defunct, the dataset is
available in the supplementary code and data tar bundle).
Probe annotations were reconstructed using Bioconductor [67]
package annotate. Contigs not mapped to genes in the original
data set were recovered as much as possible using the table
ArrayNomenclature_contig_accession.xls, also on Rosetta web
site. We used the original authors normalization, but ignored
the flags.
Probes mapping to the same genes were averaged in each one of
the three datasets.
Literature signatures
Whenever possible, the signatures were compiled from the
publications online supplementary tables. When not available, the
gene symbols were automatically read with an optical character
recognition system from the papers tables and figures. In rare
instances, signatures were encoded manually and double-checked.
Because gene names and symbols are changing over time, the gene
symbols of all signature genes were updated to match the HUGO
nomenclature and therefore maximize the match with microarray
gene annotations. HUGO gene symbols and their older aliases
were obtained from the file gene_info as available on May 9
th
2007 from the NCBI ftp server.
MSigBD 2.0 c2 signatures were downloaded as a *.gmt file from
the Broad Institute page www.broadinstitute.org/gsea/msigdb/
index.jsp.
Meta-PCNA index
We computed the Pearson correlation between PCNA and all
the genes in the Ge et al. [54] dataset and selected the 1% most
positively correlated, i.e., 131 genes out of 13,077, to form the
meta-PCNA signature (Table S1). The meta-PCNA index of a
tissue was computed from its expression profile by taking the
median expression of these genes.
Adjusting data for the meta-PCNA index
The expression of each gene was fitted with R’s ‘lm’ function
and each expression measurement was substituted by the sum of its
residual and its mean expression across the cohort.
Association of signatures with outcome
In order to systematically compare the published signatures to
random signatures and evaluate the relation between outcome
association and meta-PCNA, we needed an outcome association
estimation procedure that is robust and fully automated. We
Figure 5. Purging cell cycle genes from a signature does not
rule out proliferation signals. Distribution of the correlations with
meta-PCNA of genes in the Embryonic Stem Cell Module (blue, ref. [15]),
of the correlations of the same module with its cell cycle genes
removed (red) and of all of the genes spotted on the microarray (black).
doi:10.1371/journal.pcbi.1002240.g005
Figure 6. Reproducible outcome predictions across end-points and cohorts. Each dot represents a published signature. A) Hazard ratios. B)
Log rank p-values. Lower panels give correlation coefficients for corresponding scatter plots in the symmetric upper panels. OS, overall survival; RFS,
recurrence-free survival. NKI, data from ref. [2]; LOI, data from ref. [56].
doi:10.1371/journal.pcbi.1002240.g006
Random Signatures Are Prognostic in Breast Cancer
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them the most sensitive and stable one. This is described in
Supporting Information (Text S1), only the selected method is
described here. It consists in computing the first principal
component (PC1) of the signature (with R’s prcomp) and then
split the cohort according to the median of PC1. Probes mapping
to the same gene were averaged and, following Ramaswamy et al.
[57], data were median polished (R’s medpolish) before the
dimension reduction step.
Supporting Information
Dataset S1 Script and data underlying this paper (size
is 87 MB, unpack with UNIX bunzip2 then ‘tar xvf’).
(BZIP2)
Table S1 The meta-PCNA signature.
(PDF)
Text S1 Supplementary Information.
(PDF)
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